Anuh Pharma Limited has informed the Exchange about Investor Presentation
ANUHPHR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Anuh Pharma reported FY26 revenue of Rs. 776 Cr, up 15.66% YoY, driven by strong volume growth and expansion into regulated markets. However, profitability declined with EBITDA margin contracting to 8.56% from 10.64% in FY25, and PAT fell 13.32% YoY to Rs. 41.05 Cr. The company successfully completed USFDA and EU GMP inspections with zero 483 observations. Production volumes reached a record 1,733 MT (up 24.99% YoY) with capacity expanded to 2,400 MTPA. Revenue mix is ~46% exports and ~54% domestic. Management expects steady growth of 15-20% per annum going forward, supported by new product development including Vonoprazon Fumarate, Pretomanid, and Edoxaban Tosylate.
While revenue growth remains strong at 15.66%, the sharp margin contraction to 8.56% EBITDA and 13.32% PAT decline are concerning for shareholders. The successful regulatory inspections and capacity expansion provide a solid foundation, but cost pressures need to be addressed to improve profitability.